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ABSTRACT
Poly (ADP-ribose) polymerase-1 (PARP-1) is a cellular enzyme involved in genome stability and
transcriptional regulation. The role of this protein in HIV-1 infection is largely controversial.
Some reports indicated a fundamental role of PARP-1 in HIV-1 DNA integration and results from
other laboratories do not support these conclusions. An important characteristic in all these
experiments is that the HIV-1 target cells that were used express, in addition to PARP-1, the
functional homologue PARP-2. We evaluated the role of PARP-1 in the chicken B
lymphoblastoid cell line DT40. These cells naturally lack PARP-2 and support the early steps of
HIV infection. We have observed that DT40 PARP-1 -/- cells was significantly more susceptible
to infection with HIV- and murine leukemia virus (MLV)-derived viral vectors than their wild type
counterpart.

Expression of human PARP-1 in DT40 PARP-1 -/- cells decreased retroviral

susceptibility to wild type levels, while expression of human PARP-2 has only a partial effect.
Analysis of the retroviral life cycle by real time PCR indicated that levels of retroviral provirus
were similar in DT40 wild type, PARP-1 -/-, and PARP-1 -/- cells expressing human PARP-1.
These results, suggested that retroviral latency was established in cells expressing PARP-1.
Treatment of HIV- or MLV-infected cells with the histone deacetylase inhibitor sodium butyrate
or the DNA methyl transferase 1 inhibitor 5-azacytidine suppressed the differences in retroviral
transgene expression observed in cells expressing or not PARP-1.
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Chapter 1
BACKGROUND AND SIGNIFICANCE

The HIV pandemic. Without a doubt, the Human Immunodeficiency Virus (HIV) pandemic is the
most serious infectious disease challenge to public health today. According to the most recent
AIDS epidemic updates (2010), 33.3 million people are living with HIV, whereas 2.7 million
newly infection and 1.8 million deaths were reported just in this year. This trend in the infection
determines that the daily rate of new infections worldwide surpasses 7,000 persons worldwide
and the daily mortality rate is over 5,700 persons (15).
Though there has been significant progress in HIV research, treatment and prevention, HIV
continued infection and mortality rates outpace that progress, and the disease remains at
pandemic levels. Advances in antiretroviral drugs have significantly reduced in AIDS-related
deaths, delayed the progression of the HIV infection to AIDS and diminished the rates of HIV
transmission (15, 47). However, the current antiretroviral drugs do not target latent infection
and therefore cannot eradicate HIV-1 infection.

Therefore there is an important need of

understanding the HIV latent infection to design drugs that specifically target this condition. This
thesis focuses on the characterization of molecular mechanisms of HIV-1 latency.

HIV Life cycle. HIV is a retrovirus that is part of the Lentivirus genus, of the retroviridae family.
HIV is able to enter the cell through a viral – cell membrane fusion mechanism. Fusion occurs
through the interaction of viral glycoproteins that are present in the envelope and a receptor and
co-receptors in the host cell membrane. The specific viral glycoproteins involved in this process
are gp120 and gp41, and the cellular membrane receptors CD4 and coreceptors CCR5 or
1

CXCR4. Upon fusion, the virus uncoats and its single-stranded RNA genome is immediately
reverse-transcribed into a double-stranded DNA copy. The viral DNA binds to host and viral
proteins that are well define form the pre-integration complex. This complex is transported into
the nucleus, where the viral DNA integrates into the host genome. Viral DNA integration is
catalyzed by the viral enzyme integrase (IN), which performs two enzymatic activities essential
for viral integration; 3’ processing and DNA strand transfer of the DNA copy of the viral genome
into the host genome. 3’ processing of the linear viral genome occurs right after reverse
transcription when a dinucleotide from each end of the HIV-1 genome end is cleaved off, leaving
two-nucleotides long single-stranded regions on each end of the viral DNA (54,55). IN also
catalyzes the transfer of the viral DNA strand into the host DNA. During viral DNA integration
the host DNA is damaged and DNA repair is required for completion of integration (56).
However, the repair pathway(s) is involved is not yet known. Only after viral DNA integration the
viral genome is efficiently transcribed to produce new viral progeny. This determines that viral
DNA integration is essential for retroviral infection. Transcription of the HIV genome is driven
from the viral promoter located at the 5’ long terminal repeat (LTR) (54).

Molecular mechanisms of HIV latency

Long-term HIV̂1 reservoirs are generated early

during primary infection and have been estimated to be approximately 106 -107 cells (12)
carrying an average of 3-4 proviruses per cell (28). This viral reservoir represents a major
obstacle to the eradication of HIV-1 infection by the immune system or the most effective
therapeutic interventions (14, 50). Although pre-integration and post-integration mechanisms of
latency have been described, post-integration latency seems to be more relevant for persistent
HIV-1 infection since the short-half life of non-integrated HIV-1 genomes (14). The main
mechanisms maintaining HIV-1 latency ultimately regulates its transcription. Two main
mechanisms for transcription to occur are for the chromatin microenvironment at the integration
2

site and the availability of transcription factors are important mechanisms (14, 48). The
presence of strong host promoters at the integration site could lead to different types of
transcriptional interference, whereas integration in transcriptionally repressed areas could lead
to epigenetic modifications that suppress viral gene expression (48). These modifications
include DNA CpG (Cytosine phosphate Guanine) methylation and specific histone posttranslational modifications (14, 23, 24). The DNA methylation pattern is maintained during DNA
replication by the activity of DNA methyltransferase 1. The process of DNA methylation occurs
when the DNA base cytosine gets methylated and converted to a 5-Methylcytosine. Methylated
cytosine at CpG islands are docking sites for methyl-binding protein that in turn tether chromatin
remodeling complex (CS) that imprint modifications in the chromatin structure, thereby limiting
the accessibility of the DNA to the transcriptional machinery. In addition to recruiting chromatin
remodelers, DNA methylation can directly limit the access of the transcriptional machinery to the
promoters (11, 44).

Molecular mechanisms of LEDGF/p75 in HIV infection LEDGF/p75 is a nuclear protein that
belongs to the hepatoma-derived growth factor family, composed by other seven members (20,
40, 53). This protein is tightly bound to the chromatin, and this subcellular localization is
essential for its cellular and virological roles. LEDGF/p75 is a cellular cofactor of HIV-1 DNA
integration and therefore infection and also has a not very well characterized role in
transcriptional regulation (41, 56). Nuclear localization of LEDGF/p75 is mediated by a nuclear
localization signal during cellular interphase and during cell division through its chromatin
binding domain (43, 44). This domain is composed by the PWWP domain and two AT hook
motifs (43). All these regulatory regions are located in the N-terminal region of LEDGF/p75. In
the C-terminal region of this protein is present the integrase binding domain that is involved in
the interaction of LEDGF/p75 with different cellular proteins and with lentiviral integrases (7, 8,
3

14, 45). The ability of LEDGF/p75 to bind to chromatin during all the phases of the cell cycle and
to interact with different proteins determines the chromatin tethering role of this protein. This role
is central in both the HIV co-factor activity and the role in transcription of LEDGF/p75. In
addition, other regions of the protein are involved in the HIV co-factor activity in a chromatin
tethering-independent manner. These are two evolutionarily conserved regions in the Nterminus of LEDGF/p75, CR1 and a phosphorylated serine cluster in CR3. It has been
postulated that this regions could serve as docking sites for other cellular proteins involved in
HIV-1 DNA (23).

Role of PARP-1 in CpG DNA island methylation. Poly (ADP-ribose) polymerase (PARP)-1 is
a nuclear enzyme that belongs to a family composed by seventeen members. These enzymes
synthesize Poly (ADP) ribose (PAR) using Nicotinamide adenine dinucleotide (NAD+) as a
substrate. PARP-1 modular structure has three zinc fingers that form part of the DNA binding
domain, a nuclear localization signal (NLS), an auto modification domain, and a binding domain
for NAD+ (catalytic site). The activity of DNA methyltransferase 1 is regulated by PARP-1. This
enzyme catalyzes the synthesis and transfer of poly ADP ribose polymers (Parylation) to many
different proteins in the cell including PARP-1 itself (at the automodification domain) (1, 32, 33).
The level of parylated proteins is tightly regulated by the activity of poly (ADP-ribose)
glycohydrolase (PARG) that degrades this polymer. Parylated PARP-1 has been demonstrated
to bind DNA methyltransferase 1 inhibiting its activity (10), therefore PARP-1 negatively
regulates DNA methylation at CpG islands.

Role of PARP-1 in HIV-1 infection. A role of PARP-1 in HIV DNA integration has been
proposed, however this function is a matter of intense debate. Contradictory data have been
4

reported using either human- or mouse- derived primary or tumor cell lines in which functional
PARP-1 has been depleted by siRNA expression, gene knockout, pharmacological inhibition, or
the use of dominant mutants. In some of these experiments PARP-1 seems to be required for
HIV-1 DNA integration, whereas in others it is reported to be dispensable or even to impair this
viral process (3, 5, 17, 18, 21, 30, 51). However, an important caveat in all these experiments is
that the HIV-1 target cells used express PARP-2 in addition to PARP-1. Due to the functional
overlap between these enzymes (41), PARP-2 activities may mask a role of PARP-1 in HIV
infection. The PARP-1 enzymatic activity is believed to be significantly augmented following
DNA damage are cellular enzymes implicated in genome stability and transcriptional regulation
(1, 2). These enzymes exhibit overlapping and specific functions (32-34). Functional
redundancy between PARP-1 and -2 is illustrated by the fact that PARP-1 and PARP-2 double
knockout mice exhibit early embryonic lethality (41). Although PARP-1 has the preponderant
role, both enzymes participate in the detection, signaling, and repair of DNA strand breaks
caused by genotoxic insults (20).
This thesis will focus on understanding the molecular mechanisms implicated in the novel
activity of PARP-1 that we have discovered in our laboratory.
Significance. Advances in antiretroviral drugs have led to a significant reduction in AIDSrelated deaths, delayed the progression of the HIV infection to AIDS and diminished the rates of
HIV transmission (15, 47). However, the current antiretroviral drugs do not target latent infection
and therefore can’t eradicate HIV infection. Identification of the molecular mechanisms
implicated in HIV latency, the focus of this thesis, is essential for the development of new drugs
to eradicate or prevent the establishment of this viral reservoir. Long-term HIV̂1 reservoirs are
generated early during primary infection (28). This viral reservoir represents a major obstacle to
eradication of HIV infection by the immune system or the most effective therapeutic
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interventions (14, 50). Therefore understanding how latent infection is established will
definitively impact our ability to eradicate HIV infection.
Specific aims.
This thesis focuses in understanding the role of PARP-1 in HIV infection. Our laboratory has
identified PARP-1 as a LEDGF/p75-interacting protein in two independent proteomic analyses
of LEDGF/p75. However, the implication of this interaction for HIV infection was unknown.
Therefore, our research project focused in determining the role of PARP-1 in HIV infection. To
uncover this role we have completed three different specific aims:
Specific aim 1. To define the regions of LEDGF/p75 required for the interaction with PARP-1.
We evaluated a panel of LEDGF/p75 mutants by immunoprecipation to establish the regions
interacting with PARP-1
Specific aim 2. To determine the role of PARP-1 and PARP-2 in HIV and MLV infection. In this
specific aim we evaluated the susceptibility to retrovirus infection of cells lines lacking the
expression of PARP-1 and/or PARP-2 or that were treated with a PARP pharmacological
inhibitor. The step of the HIV viral life affected by PARP-1 was also determined.
Specific aim 3. To establish the role of epigenetic mechanism in the effect of PARP-1 on
retroviral infection. Our results in specific aim 2 indicated that PARP-1 induced retroviral latency.
Therefore, we determined the implication of DNA methyltransferase 1 and Histone Deacetylase
in the viral activity of PARP-1 using pharmacological inhibitors of these enzymes.

6

Chapter 2
MATERIALS AND METHODS
Cell lines and Viruses. DT40-derived cell lines: DT40-derived cells were kindly provided by
Shunichi Takeda (Crest Laboratory, Department of Radiation Genetics, Faculty of Medicine,
Kyoto University, Sakyo-ku, Kyoto, Japan). DT40 is a chicken B lymphocyte cell line (wild type
cells, WT). KO cells are DT40 PARP-1 -/- cells. KO cells were engineered to express human
PARP-1 (h-1) or human PARP-2 (h-2) (22) .
Human cells: Jurkat and Supt1 cells are CD4+ T cell lines. HEK 293T are epithelial cells.
LEDGF/p75-deficient cell line TL3 derives from the Supt1 cell line (37) and were engineered to
expresses Flag-tagged LEDGF/p75 WT or mutants, or LEDGF/p52 (19).
Retroviral Vectors: MLV luc and HIV Trip luc (or eGFP) derived from murine leukemia virus
(MLV) and HIV, respectively, are single-round infection viruses that express luciferase (or
eGFP) from an internal CMV promoter (Fig. 5a), these vectors were used to challenge DT40derived cells. Human-derived cell lines were infected with single-round infection viruses that
express luciferase from the HIV LTR promoter (Hluc) (37). Production of these vectors has been
previously described (19). Briefly, HEK 293T cells were transfected with a plasmid expressing
the genome of the viral vector (pTrip luc or eGFP), the packaging plasmid pCMVΔR8.91, and
the envelope plasmid pMD.G encoding the vesicular stomatitis virus glycoprotein G. Production
of Hluc required transfection of HEK 293T cells with pHluc and the envelope plasmid pMD.G.
For the production of MLV-derived vectors the packaging cell line Phoenix A was transfected
with a plasmid expressing the genome of the viral vector (pMLV luc) and the envelope plasmid
pMD.G. Seventy-two hours after transfection the viral supernatant was collected, filtered and
concentrated by ultracentrifugation on a sucrose cushion. Different doses of each viral vector
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were assayed in single-round infectivity assays to select a viral dose that produce relevant
levels of the transgene expression without causing cellular toxicity.

Immunoblotting. Cellular lysates were resolved by SDS-PAGE and transferred overnight to
PVDF membranes at 100 mAmp at 4°C.

Membranes were blocked for one hour in TBS

containing 10% milk and then incubated with the corresponding primary antibody that was
diluted in TBS-5%, milk-0.05%, and Tween 20 (antibody dilution buffer). PARP-1: 2C10 (dilution
1/1000), PARylation: sc-56198, Santa Cruz (dilution 1/250), PARP-2: sc-133886, Santa Cruz
(dilution 1/500), FLAG: M2, Sigma (Diluted 1/500), alpha tubulin: clone B-5-1-2, Sigma (dilution
1/4000). Membranes were incubated overnight at 4°C with the corresponding antibodies.
Primary antibody-bound membranes were washed in TBS-0.1% Tween 20 three times for 5
minutes and bound antibodies were detected by chemoluminescence with specific secondary
antibodies coupled to HRP.

DNase extraction of chromatin-bound proteins (S2 fraction).

Previously described

procedures (39) were followed with minor modifications. Figure 3 of reference (39) shows a
validation experiment where multiple proteins located in different cellular compartments were
evaluated. Briefly, 3x106 TL3-derived cells expressing different LEDGF/p75 WT and mutants, or
LEDGF/p52 were washed in PBS and lysed for 15 mins on ice in 100ul of CSK I buffer (10mM
Pipes pH6.8, 100mM NaCl, 1mM EDTA, 300mM sucrose, 1mM MgCl2, 1mM DTT, 0.5% Triton
X-100) containing protease inhibitors (final concentration: leupeptine 2ug/ml, aprotinin 5ug/ul,
PMSF1mM, pepstatin A 1ug/ml). Cells lysed in CSKI buffer were centrifuged at 1000g for 6
mins at 4°C and the pellet resuspended in 100ul of CSK II buffer supplemented with protease
inhibitors, 4 units of turbo DNase (Ambion) and 11ul of 10X turbo DNase reaction buffer. DNase
treatment of this pellet was conducted at 37°C for 30 mins and then followed by extraction with
8

(NH4)2SO4 250mM for 15 mins at 37°C. The DNase/ (NH4)2SO4 treated sample was centrifuged
at 22,000g for 3 mins and the supernatant saved for analysis (chromatin-bound fraction, S2).

Immunoprecipitation. The interaction of the LEDGF/p75 with PARP-1 was evaluated by
immunoprecipitation using the DNase extracted chromatin-bound proteins (S2 fraction). S2
fractions were clarified by centrifugation at 22,000g for 3 mins and the supernatant adsorbed
with goat anti mouse Igs-coated magnetic beads (Pierce) for 30 mins at 4ºC. Goat anti mouse
Igs-coated magnetic beads (100ul) were also incubated for 20 mins on ice with 3ug of anti-Flag
Mab, or LEDGF/p75 (BD Transduction Laboratories), or anti-Myc MAb (negative control, clone
9E10, Covance) diluted in CSKI buffer. Then, the primary antibody-loaded beads were
separated from the unbound antibodies, mixed with the preadsorbed S2 fraction and rotated for
3 hrs at 4°C. After this incubation, beads were washed three times in CSKI buffer and bound
proteins eluted by boiling in 30ul of Laemmli sample buffer. Immunoprecipitated proteins were
analyzed by immunoblotting with anti-PARP-1 or anti-LEDGF/p75 Mabs.

To evaluate the

strength of the interaction LEDGF/p75-PARP-1, the S2 fraction used in the LEDGF/p75immunoprecipitation were supplemented with different concentrations of NaCl.

HIV-1 DNA integration analysis. Viral integration was quantified by detection of total HIV-1
cDNA (gag DNA, Fig. 6a) by real-time PCR in DT40-derived cells ten days after HIV infection.
Three completely independent experiments using two different viral preparations were
performed. In these experiments, 105 cells were infected with DNase-treated HIV Trip luc viral
supernatant and cultured for ten days. Then DNA was extracted (High pure PCR template
preparation kit, Roche) from 106 infected cells and 20ng of DNA were used for the detection of
total HIV-1 cDNA, Histone 4 DNA and 2LTR circles All these real time PCRs were performed in
9

a MiniOpticon system (Bio-rad) with primers and conditions previously described (37). Fold
change was calculated using the ∆Ct method as recommended in the thermo-cycler manual and
differences were expressed in percentage, considering the value for DT40 KO as 100%.
Single-round viral infectivity assay. Cells were plated at 1x105 cells in 500µl of culture
medium in 24-well plates and infected with different MOI’s of the different HIV- or MLV-derived
single-round infection viral vectors. Two, four, or ten days post-infection, cells were collected by
centrifugation at 1000g for six minutes and the pellet lysed in 200µl of PBS-1% on ice for ten
mins. 100ul of the cell lysate were mixed with 100µl of substrate (Bright-Glow™ Luciferase
Assay System, Promega), incubated for 10 minutes in the dark and then the luciferase activity
was quantified using a microplate luminometer. Simultaneously, cellular ATP levels were
measured in these samples by mixing 100 ul of the cellular lysate with 100µl of substrate
(Bright-Glow™ Cell Viability Assay System, Promega), incubating for 10 minutes in the dark and
then the quantifying the luminescence levels with a microplate reader luminometer. eGFP
expression in cells infected with HIV Trip eGFP were measured four or ten days after infection
by FACS.
Pharmacological Treatments. Three days after retroviral infection, 105 cells were plated in
500 ul of culture medium in a 24-well plate and treated for 24 hrs with Sodium Butyrate (5uM) or
5-Azacytidine (60uM). Then, cells were used to determine luciferase and ATP levels as
described above. 105 cells were plated in 500 ul of culture medium in a 24-well plate and treated
for 24 hrs with 3,4-Dihydro-5[4-(1-piperindinyl)butoxy]-1(2H)-isoquinoline (DPQ), a PARP
inhibitor, then cells were infected with different single-round replication retroviruses or used to
determine the cellular levels of poly ADP ribose polymers by immunoblotting as described
above. Infection was determined three days after infection by measuring the cellular levels of
luciferase and ATP, as described above.
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Chapter 3
RESULTS
Specific aim 1.
PARP-1 specifically interacts with LEDGF/p75. In two independent proteomic analyses
carried out as collaboration with two other laboratories, PARP-1 was identified as a LEDGF/p75
interacting protein (Data not shown). To verify this interaction, chromatin-bound proteins were
extracted using extensive DNase treatment [S2 fractions (39)] from CD4+ T cells that express
endogenous levels of LEDGF/p75 and PARP-1, and LEDGF/p75 was immunoprecipitated in the
presence of DNase from this DNA-free extract. An anti-Myc antibody was used as negative
control in these experiments. Then, the presence of PARP-1 in the inmunoprecipitated proteins
was evaluated by immunoblotting with specific antibodies. Using this method we demonstrated
the interaction of LEDGF/p75 with PARP-1 in the absence of DNA (Fig. 1). During apoptosis
PARP-1 is cleaved by the caspase-3,-6,-7 complex at a DEVD motif in the NLS. This cleavage
produces two protein fragments p24 and p89 that contain the N-terminal DNA binding domain
and

the

C-terminal

catalytic

region

of

this

protein,

respectively.

LEDGF/p75

co-

immunoprecipitated with the full-length (116 kDa) and the C-terminal (89 kDa) fragment of
PARP-1 protein. These results suggested that the N-terminal region of PARP-1 is dispensable
for the interaction with LEDGF/p75.
To map the LEDGF/p75 region interacting with PARP-1 CD4+ T cells severely depleted of
LEDGF/p75 (TL3 cells (37)) engineered to express different LEDGF/p75 mutants (19) or the
LEDGF/p52 splicing product were evaluated by immunoprecipitation as described above. Using
this method we determined that LEDGF/p75, but not p52, interacts with PARP-1 (Fig. 2a). Since
these splicing products share the same N-terminal region but carry a complete different Cterminus, these data suggest that LEDGF/p75 interacts with PARP-1 through the C-terminal
11

region. Therefore, a panel of LEDGF/p75 mutants lacking different structural regions in the Cterminus was evaluated (Fig. 2b).
Figure 1. Interaction of LEDGF/p75 with PARP1. Chromatin-bound proteins were extracted from

Immunoblot
kDa
95

+

CD4 T

PARP-1
(113kDa)

IP:

(Supt1

cell

line)

expressing

endogenous levels of LEDGF/p75 and PARP-1 by
extensive DNase treatment [S2 fraction (39)].

PARP-1
(89kDa)

72

cells

LEDGF/p75

was

immunoprecipitated

in

the

presence of DNase with a specific monoclonal

LEDGF/p75

antibody

and

immunoprecipitated

proteins

analyzed for the presence of PARP-1 and

myc LEDGF/p75

LEDGF/p75

by

immunoblotting.

An

anti-Myc

monoclonal antibody was used as negative control in the immunoprecipitation reaction. Full-length PARP1 (113 kDa) and a caspase-generated proteolytic fragment corresponding to the C-terminal region (89
kDa) of the protein were specifically co-immunoprecipitated with LEDGF/p75.

Importantly, only a mutant lacking the IN biding domain (IBD) was unable to interact with PARP1, indicating that PARP-1 binds to this region of LEDGF/p75. We further determined whether
other regions in the N-terminus of LEDGF/p75 were also implicated in the binding to PARP-1
(Fig. 2a and b). Interestingly, LEDGF/p75 mutants lacking the PWWP domain did not interact
with PARP-1. These results then establish that interaction of LEDGF/p75 with PARP-1 require
two independent protein regions of LEDGF/p75, mainly the IBD and PWWP domains. Since the
PWWP domain is part of the chromatin-binding domain of LEDGF/p75 and PWWP mutants are
defective in chromatin binding (39) we postulate that the defective PARP-1 interaction of
mutants lacking the PWWP domain could be because the interaction of LEDGF/p75 with PARP1 requires that LEDGF/p75 is tightly bound to the chromatin. Alternatively, the IBD and the
PWWP domain could form a surface of PARP-1 interaction in the LEDGF/p75 folded protein. In
support of this possibility our lab has reported that both PWWP and IBD contain residues
targeted for post-translational modification by the small ubiquitous-like modifier (SUMO) (9),
therefore these two protein domains could be in the folded protein closer than expected by their
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location in the primary structure of the protein. In further support of the interaction between the
N-terminus and the C-terminus of LEDGF/p75 it has been observed that antibodies binding to
the N-terminus of denature LEDGF proteins (immunoblotting) can immunoprecipitate native
LEDGF/p52 but not native LEDGF/p75 (36).

A

LEDGF

IP:

p52

LEDGF

LEDGF

LEDGF

p75 myc PWWP CR1 CR1b

p75

myc CR4

IBD CR5.1 CR6

Immunoblot
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95

PARP-1
Ig light chain

26

HIV genome

B
Main
chromatin-binding domains
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ß-barrel
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PWW
helice

N
L
S

CR1

AT

CR2

CR1b

CR3

IBD

CR5.1

CR6

IN-binding
domain

Chromatin

+

Figure 2. LEDGF/p75 regions involved in the interaction with PARP-1. (a) LEDGF/p75-deficient CD4

T cells (Supt1 cell line) engineered to express different C-terminally Flag-tagged LEDGF/p75 mutants or
the LEDGF/p52 splicing variant were used in these experiments. Chromatin-bound proteins were
extracted from these cells by DNase treatment (S2 fraction) and LEDGF/p75 was immunoprecipitated in
the presence of DNase with anti-Flag monoclonal antibody. Immunoprecipitated proteins were analyzed
for the presence of PARP-1 using a specific monoclonal antibody by immunoblotting. An anti-Myc
monoclonal antibody was used as negative control in the immunoprecipitation reactions. LEDGF/p75 but
not LEDGF/p52 interacts with PARP-1. LEDGF/p75 mutants lacking the IN binding domain (IBD) or the
PWWP domain failed to interact with PARP-1. Detection of the Ig light chain was used to demonstrate
that similar amount of antibodies were immunoprecipitated in each of the experiments. (b). LEDGF/p75
protein regions. CRs represent charged regions in the LEDGF/p75 molecule that are also evolutionarily
conserved.
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The interaction of LEDGF/p75 with HIV IN also requires the IBD (Fig. 2b). This interaction is
very strong occurring even in the presence of 500 mM NaCl (4). To determine the strength of
the interaction of LEDGF/p75 with PARP-1, immunoprecipitations were carried out with DNAfree chromatin-bound proteins in the presence of different NaCl concentrations. Similarly to
LEDGF/p75-IN interaction the interaction of LEDGF/p75 was very strong (Fig. 3). These data
also demonstrated the specificity of this protein interaction.
Figure 3. Effect of the ionic

IP:

LEDGF/p75
NaCl (mM)
200 300 400

strength on the LEDGF/p75-

myc
NaCl (mM)
200 300 400

PARP-1 interaction. Chromatinbound proteins were extracted
+
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Input

Immunoblot

kDa
95

PARP-1
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LEDGF/p75

and

PARP-1

by

extensive DNase treatment (S2
fraction).

LEDGF/p75

was

immunoprecipitated in the presence of DNase and different concentrations of NaCl using a specific
monoclonal antibody. Immunoprecipitated proteins were analyzed for the presence of PARP-1 by
immunoblotting.

An

anti-Myc

monoclonal

antibody

was

used

as

negative

control

in

the

immunoprecipitation. LEDGF/p75 strongly interacts with PARP-1.

Specific aim 2.
Role of PARP-1 and PARP-2 in retroviral infection.
As described previously, the exact role of PARP-1 and PARP-2 in HIV integration remains
unclear. . Because the functional overlap between these enzymes (41), PARP-2 activities could
mask a role of PARP-1 in HIV infection. In order to solve this limitation, we analyzed the function
of PARP-1 in HIV infection in the chicken B lymphocyte cell line DT40. These cells naturally lack
PARP-2 expression and are viable after PARP-1 knockout (22) (Fig. 4), in addition they are a
reliable model to study the early events of the HIV life cycle, including uncoating, reverse
transcription, DNA integration and HIV transgene expression (6, 42, 43).
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Figure 4. Expression of PARP-1 and PARP-2 in DT40-derived cells. Cells (0.6 x 10 /lane) were lysed
in Laemli buffer and analyzed by immunoblotting for the expression of PARP-1 and PARP-2. Alpha
tubulin

kDa

was

detected

as

a

loading control. h-1 cells express

Parp-1

95
70

substantially higher amounts of
PARP-1 as compared to WT

Parp-2

55
40

cells. Arrow heads indicate the
different proteins detected.

α tubulin
WT

KO

h-1

h-2

DT40 PARP-1 +/+ (WT), DT40 PARP-1 -/- (KO), (22) were challenged with single-round
infection HIV reporter viruses expressing eGFP or luciferase from an internal cytomegalovirus
immediate-early (CMV) promoter [HIV Trip eGFP or Luc, respectively (37) (Fig. 5a)] and
infection was evaluated two, four, and ten days later by measuring eGFP or luciferase
expression in the challenge cells. As a control, luciferase levels were normalized to cellular ATP
levels to exclude any contribution of a differential cell number or cellular viability in the
challenged cells at the time of the evaluation of HIV infection. This control was included in all
the experiments described in this thesis that involve determination of luciferase. Two days after
infection, HIV-derived transgene expression was readily detectable in the challenged cells and
no differences, in transgene expression were observed between the cell lines analyzed (Data
not shown) At this early time point transgene expression from non-integrated and integrated
viruses could be detected. Therefore to focus our analysis only on integrated viruses, infection
was also evaluated four and ten days postinfection. Importantly, at these later time points, KO
cells showed between 4-5 times more susceptibility to HIV infection than WT cells (Fig. 5b and
5c).
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We extended our studies to KO cells engineered to express human PARP-1 (h1) or human
PARP-2 (h2) and to the retrovirus murine leukemia virus (MLV), the MLV was used as a test to
understand if PARP-1 and 2 are susceptible to HIV or other retroviruses. The MLV reporter
virus used expresses luciferase from an internal CMV promoter (MLV luc, Fig. 5a) (37). WT,
KO, h1, and h2 cells were challenged with HIV Trip luc or MLV luc and infection was evaluated
four days after challenge by measuring luciferase. Data in fig 5c indicate that KO cells were
between five (HIV) to 18 (MLV) fold more susceptible to retroviral infection than cells expressing
chicken PARP-1 (WT cells). This increased susceptibility was completely reduced to wild type
levels after reexpression of human PARP-1. However, the effect of human PARP-2 was only
partial (fig 5c). These results clearly indicate that PARP-1, and to a lesser extent PARP-2,
impairs HIV and MLV infection, suggesting a functional redundancy of these two human
enzymes in retroviral infection. These results also indicated that the effect of PARP-1 on
retroviral infection is unlikely to be dependent only on its interaction with LEDGF/p75 (Fig. 1-3)
since this cellular cofactor does not interact with MLV IN (38) or influence MLV infection (37).

HIV CMVp-driven luciferase

A
hCMVp R U5

gag/ RRE

cPPT CMV

Luciferase

U

R U5

MLV CMVp-driven luciferase
hCMVp R U5

Figure 5A.

gag/

Luciferase

CMV

U

R U5

Role of PARP-1 and PARP-2 in retroviral infection. (a) Structure of the plasmids

expressing HIV- and MLV-derived single-round infection viral vectors used in the experiments described
in this thesis.
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h-2

Figure 5C. Role of PARP-1 and PARP-2 in retroviral infection. (c) Fold infectivity observed in singleround infection experiments of DT40 wild type (WT) and PARP-1 -/- (KO) cells and KO cells engineered
to express human PARP-1 (h-1) or human PARP-2 (h-2) with HIV- or MLV-derived viral vectors
expressing luciferase. Infectivity was determined four days after infection by measuring transgene
expression. Luciferase activity is expressed relative to the levels found in WT cells. In the experiments
represented in Fig. 5 a-c, ATP cellular levels were measured in parallel to luciferase measurements to
normalize the luciferase activity to the cell number and viability of the infected cells. Standard deviations
in the experiments included in fig 5 represent triplicate measurements of transgene expression. Results
in fig. 5 are representative of more than five independent experiments performed with different viral
preps.

Effect of PARP-1 on the HIV life cycle. The fact that the differences in susceptibility to HIV
infection between cells expressing or not PARP-1 were not observed after forty-eight hours of
infection suggests that the effect of PARP-1 on retroviral infection occurs at or after viral DNA
integration. In order to evaluate the step of the viral life cycle affected by PARP-1 we measured
by real time PCR the levels of different forms of the HIV genome. Following entry the singlestranded RNA genome is reverse transcribed to a DNA copy. This DNA copy associates with
viral and cellular proteins, forming the pre-integration complex that is imported into the nucleus
where the viral DNA integrates into the host genome. The nuclear viral DNA that fails to
integrate is then circularized or degraded. Eventually circular forms are also degraded or diluted
during cell division. Therefore, after several days postinfection only the integrated viral DNA
persists. To measure the viral genome by quantitative real time PCR we used a set of primers
that hybridize on the gag DNA in the HIV genome (Fig. 6a). Because this DNA fragment is
present in both the integrated and the non-integrated forms of the viral genome, we will
determine the gag DNA levels ten days after infection to favor detection of integrated viral DNA.
In addition, 2LTR circles, the predominant non-integrated form of the viral genome, were also
measured (Fig. 6b). To calculate the integrated fraction of gag DNA we normalized the levels of
gag DNA to the levels of 2LTR circles that were previously normalized for the levels of histone 4
18

DNA, a loading control. Using this strategy, we determined that the levels of integrated HIV DNA
were slightly higher in cells expressing PARP-1 than in knockout cells (Fig. 6b). These data
indicated that PARP-1 impairs HIV infection at a postintegration step.

HIV RNA

A
Reverse Transcription
Gag DNA PCR
HIV cDNA

Nucleus

Gag DNA PCR

HIV provirus

2LTR PCR

Gag DNA PCR
HIV 2LTR circles

Gag DNA = Provirus DNA + 2 LTR DNA

Gag DNA / 2LTR DNA = Provirus

Figure 6A. Levels of HIV proviral DNA in cells differing in PARP-1 expression (a) Real time PCR
strategy used to calculate HIV provirus levels. Notice that the gag DNA PCR used can detect integrated
and non-integrated forms of the viral genome. The extranuclear linear viral genome is very transient with
a half-life of less than 24 hrs, the 2LTR circles can persist longer (48 -72 hrs) whereas the integrated viral
genome is permanent.
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Figure 6B. Levels of HIV proviral DNA
in cells differing in PARP-1 expression
(b). Quantification of the HIV provirus
levels. DT40 wild type (WT), PARP-1-/(KO), and PARP-1-/- expressing human
PARP-1 (h-1) cells were infected with
HIV Trip luc and ten days later the levels
of total HIV cDNA, 2LTR circles, and
histone 4 were quantified by real-time
PCR. Total HIV cDNA levels were
normalized

to

histone

4-normalized

2LTRs levels. Standard deviations were
calculated

using

triplicate

PCR

experiments. The data are representative
of three independent infections.

PARP-1

WT

KO

h-1

Effect of pharmacological inhibition of PARP-1 on HIV infection. PARP-1 catalyzes the
synthesis of poly ADP ribose from NAD+, in addition, other non-enzymatic activities have been
described in this enzyme (20, 45). To determine whether or not the enzymatic activity of PARP1 mediates the effects of this protein on retroviral infection, we treated the cells with 3,4Dihydro-5[4-(1-piperindinyl)butoxy]-1(2H)-isoquinoline (DPQ), a PARP inhibitor, for 24 hrs
before viral challenge. DPQ was kept in the culture medium during infection and until infectivity
was analyzed. Using this approach we studied Jurkat and 293T cells, as well as the DT40-
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derived cells WT, KO, and h-1. In all these experiments we observe no differences between the
treated and the non-treated cells (Fig. 7a).

A
DPQ
O uM
6O uM

293T Jurkat

WT

H1

HIV

KO
WT
DT40

H1

KO

MLV

Figure 7A. Effect of pharmacological inhibition of PARP-1 on its viral activity. (a) DT40 WT, KO,
and h-1 cells were treated or not with DPQ (60 uM) for 24 hrs and then infected with HIV- or MLV-derived
viral vectors. 72 hrs after infection the luciferase levels were measured in the treated and not treated
cells. Luciferase levels were normalized to cellular ATP levels measured in the same samples.
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The studied cells were treated or not with DPQ for 24 hrs and the basal levels of poly ADP
ribose were measure by immunoblotting with an specific antibody (Fig. 7b). Under these
conditions only a partial reduction of PARP activity was reached at the highest dose of DPQ.
Cellular cofactors interacting with the incoming HIV virions are required at extremely low levels
(37); therefore the partial PARP-1 activity present in the DPQ-treated cells could be sufficient for
affecting HIV infection. Therefore, we can not firmly exclude a role of the enzymatic activity of
PARP-1 on its viral activity.
Figure
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Because DPQ is unstable, we performed an additional experiment (Fig. 7c) in which we
pretreated the cells before infection and then we added fresh DPQ to the cells every 24 hrs until
infectivity was measured 72 hrs after infection (intensive DPQ treatment). As described above,
ATP levels in the treated and un-treated cells were determined and luciferase activity was
normalized to that. In this experiment we observed that DPQ treatment increased by 4 fold the
susceptibility of Jurkat cells to HIV infection (Fig. 7c). These results suggest that inhibition of
PARP-1 activity could increase the susceptibility of human cells to HIV infection, additionally
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supporting our previous observations in chicken cells. However, this experiment was done only
once and therefore needs to be considered as a preliminary observation. We will repeat this
experiment with a panel of human CD4+ T cells and a battery of PARP inhibitors.
Figure 7. Effect of pharmacological
inhibition of PARP-1 on its viral activity.
(c) Cells were treated as described in panel
a but fresh DPQ was added to the culture
every 24 hrs until infectivity was determine
72 hrs after viral challenged. Standard
deviations represent triplicate measurement
of luciferase levels. Data in panel (a and b)
are

representative

of

two

independent

experiments, whereas data in panel c
represent only one experiment.

DPQ (uM)

0

60

Specific aim 3.
Effect of PARP-1 on HIV silencing. PARP-1 affects HIV transgene expression without
affecting proviral formation, a hallmark of HIV latency. The most common cause of HIV latency
is transcriptional silencing of the integrated provirus by epigenetic mechanisms (8, 14, 27).
Among the different epigenetic mechanisms that regulate gene expression, CpG island DNA
methylation (8, 14) and histone deacetylation (27) are considered the leading causes of HIV
latency. In order to evaluate the involvement of these mechanisms in the effect of PARP-1 on
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retroviral infection, cells infected with HIV Trip luc or MLV luc were treated for 24 hours with
sodium butyrate, a histone deacetylase (HDAC) inhibitor, or 5-azacytidine, a DNA
methyltransferase 1 inhibitor, and the levels of luciferase and ATP were measured. Importantly,
pharmacological inhibition of HDAC dramatically eliminated the differences in transgene
expression in HIV- or MLV-infected cells that express or not PARP-1 (Fig. 8a), indicating a role
of HDAC in PARP-1-induced retroviral silencing. Since HDAC are recruited to methylated DNA,
we also investigated the role of DNA methyltransferase 1 in the PARP-1 viral activity.
Interestingly, although treatment with 5-azacytidine removed the differences of transgene
expression between cells expressing or not PARP-1 that has been infected with HIV or MLV
(Fig. 8b and c), the intensity of this effect was variable among different experiments. In
addition, the effect of 5-azacytidine was stronger in PARP-1 -/- (KO) cells expressing human
PARP-1 (h-1 cells) than in the DT40 wild type cells. A possible explanation for this differential
effect in WT and h-1 cells is the dissimilar levels of PARP-1 expressed by these cells, h-1
expresses substantially higher levels of PARP-1 than WT cells (Fig. 4).
In summary, these data indicated that PARP-1 induces retroviral silencing by epigenetic
mechanisms that involve the activity of HDAC and DNA methyltransferase 1.
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cells were infected with different amounts of HIV- or MLV-derived viral vector and three days after
infection the cells were treated or not with sodium butyrate (5uM) or 5-azacytidine (60uM) for 24 hrs and
the luciferase levels measured in the treated and not treated cells. Luciferase levels were normalized to
cellular ATP levels measured in the same samples. Standard deviations represent triplicate measurement
of luciferase levels. Data in panel (a) are representative of three independent experiments; data in panel
(b and c) represent only one experiment.
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Chapter 4
DISCUSSION
Our data indicate a role of PARP-1 in retroviral latent infection. In the presence of PARP-1 a
significant fraction of the retroviral proviruses result silenced by epigenetic mechanisms that
involve the activity of DNA methyl transferase 1 and HDACs. However, other proviruses escape
this negative regulation. Because PARP-1 is very abundant in the cell, its cellular levels are
unlikely to limit the effect of this enzyme on retroviral infection. These data suggest the
existence of other cellular factor(s) that opposes to the silencing effect of PARP-1.
How PARP-1 triggers retroviral silencing is intriguing. Our data clearly indicate that the activity
of DNA methyl transferase 1 and HDACs mediates the PARP-1 effect. DNA methyl transferase
1 methylates the DNA attracting DNA methyl-binding proteins that in turn recruits HDACs.
HDACs remove acetyl groups from the tail of histones condensing the chromatin and as a
consequence repressing transcription (7, 23, 25, 35, 46). However, it has also been shown that
PARP-1 reduces DNA methylation by decreasing the activity of DNA methyltransferase 1, an
effect that requires the enzymatic activity of PARP-1 (10, 53). Therefore, it is surprising that
PARP-1 will directly induce retroviral silencing through a mechanism that involves DNA methyl
transferase 1 activity. A possibility is that PARP-1 induces retroviral silencing by an indirect
mechanism. For example, PARP-1 could promote the integration of retroviruses into
heterochromatin and as a result the epigenetic marks of the neighbor chromatin could be
extended to the proviruses. In this regards it has been reported a role of PARP-1 in promoting
HIV-1 integration in centromeric regions (30). It is well established that retroviral integration into
heterochromatin results in retroviral silencing (27, 31).
PARP-1 could promote retroviral DNA integration into heterochromatin by impairing the activity
of cellular factors driving retroviral DNA integration into euchromatin.
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PARP-1 has been

reported to enzymatically modify over seventy different cellular proteins (26, 52) including,
histones, chromatin remodeling proteins, transcription factors, and DNA repair proteins. In this
regard, we have demonstrated the interaction of PARP-1 with LEDGF/p75 (Fig. 1-3), a cellular
factor that promotes HIV DNA integration into actively transcribed chromatin (13, 40). It is
possible that PARP-1 could impair the HIV cofactor activity of a fraction of the LEDGF/p75 pool,
therefore causing a reduction of integration into actively transcribed chromatin. In this case, the
HIV preintegration complex would preferentially interact with cellular cofactors that drive HIV
DNA integration into heterochromatin instead of with LEDGF/p75 that promotes integration into
euchromatin. In support of this possibility it has been demonstrated at the genomic level that
LEDGF/p75 is not amenable to HIV DNA integration at every location of the genome where this
protein is present (16). Similarly, PARP-1 could modify the activity of cellular factor(s) involved
in integration of MLV into euchromatin.
Conclusions.
In conclusion, we identified a novel role of PARP-1 in retroviral infection. Our data clearly
indicate that PARP-1 promotes viral latency by epigenetic mechanisms that involve the activity
of DNA methyltransferase 1 and Histone Deacetylases. We identified that the PWWP and the
IN binding domain of LEDGF/p75 and the C-terminal region of PARP-1 are required for the
LEDGF/p75-PARP-1 interaction. We also determined that PARP-1 and PARP-2 have an
overlapping role in promoting retroviral latent infection. However, PARP-1 is more active than
PARP-2 in this novel function. The implication of the enzymatic activity of PARP-1 or -2 in this
function remains uncertain. Finally we established that PARP-1 induces retroviral latency by a
mechanism that involves the enzymatic activity of DNA methyltransferase 1 and Histone
Deacetylases.
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